慢性肾脏病中缺氧及缺氧诱导因子天冬酰胺酰羟化酶调控的演变
研究利用蛋白尿性慢性肾脏病(CKD)模型和单侧纤维化梗阻性肾病模型,以哌莫硝唑评估缺氧、三维显微CT评估血管化,并分析217例1至5期CKD活检数据库及随机抽取的15例不同严重程度CKD活检,探讨缺氧与HIF通路及天冬酰胺酰羟化酶FIH在CKD中的变化,并在体外和体内调节FIH活性。
要点
- 早期CKD阶段不以缺氧或HIF活化为特征,晚期CKD可见部分缺氧区域但不与纤维化共定位。
- 小鼠和人类CKD中HIF通路下调且FIH表达随疾病严重程度增加。
- 体内药物抑制FIH可提高对照和CKD动物的肾小球滤过率,并与纤维化发展减少相关。
核心结论
- 缺氧和HIF活化在CKD进展中的致病作用受到质疑。
- 药物下调FIH在蛋白尿性肾脏疾病中似乎有前景。
研究设计与样本
- 采用进行性蛋白尿性CKD模型和单侧纤维化梗阻性肾病模型,以哌莫硝唑评估缺氧、三维显微CT评估血管化。
- 分析217例1至5期CKD活检数据库,并随机收集15例不同严重程度CKD活检评估FIH表达。
- 在体外和体内用药物方法调节FIH活性以评估其在CKD中的相关性。
主要发现
- 在蛋白尿性CKD模型中,早期CKD阶段不以缺氧或HIF活化为特征。
- 晚期CKD阶段观察到部分缺氧区域,但这些区域不与纤维化共定位。
- 小鼠和人类中观察到HIF通路下调,同时FIH表达随CKD严重程度增加。
- 体外调节FIH影响细胞代谢,如先前所述。
- 体内药物抑制FIH提高对照和CKD动物的肾小球滤过率,并与纤维化发展减少相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The roles of hypoxia and hypoxia inducible factor (HIF) during chronic kidney disease (CKD) are much debated. Interventional studies with HIF-α activation in rodents have yielded contradictory results. The HIF pathway is regulated by prolyl and asparaginyl hydroxylases. While prolyl hydroxylase inhibition is a well-known method to stabilize HIF-α, little is known about the effect asparaginyl hydroxylase factor inhibiting HIF (FIH). METHODS: We used a model of progressive proteinuric CKD and a model of obstructive nephropathy with unilateral fibrosis. In these models we assessed hypoxia with pimonidazole and vascularization with three-dimensional micro-computed tomography imaging. We analysed a database of 217 CKD biopsies from stage 1 to 5 and we randomly collected 15 CKD biopsies of various severity degrees to assess FIH expression. Finally, we modulated FIH activity in vitro and in vivo using a pharmacologic approach to assess its relevance in CKD. RESULTS: In our model of proteinuric CKD, we show that early CKD stages are not characterized by hypoxia or HIF activation. At late CKD stages, some areas of hypoxia are observed, but these are not colocalizing with fibrosis. In mice and in humans, we observed a downregulation of the HIF pathway, together with an increased FIH expression in CKD, according to its severity. Modulating FIH in vitro affects cellular metabolism, as described previously. In vivo, pharmacologic FIH inhibition increases the glomerular filtration rate of control and CKD animals and is associated with decreased development of fibrosis. CONCLUSIONS: The causative role of hypoxia and HIF activation in CKD progression is questioned. A pharmacological approach of FIH downregulation seems promising in proteinuric kidney disease.
引用
- Faivre A, Dissard R, Kuo W, et al. Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase regulation in chronic kidney disease. Nephrol Dial Transplant. 2023. PMID: 37096392. doi:10.1093/ndt/gfad075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。